Genotyping and antifungal drug susceptibility of the pathogenic yeast Trichosporon asahii isolated from Thai patients

Mycopathologia

Volumn 169, Issue 1, 2010, Pages 67-70

  Mekha, Nanthawan ^a,b   Sugita, Takashi ^b   Ikeda, Reiko ^b   Nishikawa, Akemi ^b   Autthateinchai, Rinrapas ^a   Poonwan, Natteewan ^a   Sawanpanyalert, Pathom ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antifungal drug susceptibility; Genotype; Intergenic spacer region; Trichosporon asahii

Indexed keywords

TRICHOSPORON ASAHII;

EID: 72249098782     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-009-9225-5     Document Type: Article

References (15)

1. Guého E, Improvisi L, de Hoog GS, Dupont B. Trichosporon on humans: a practical account. Mycoses. 1994; 37: 3-10.
2. Sugita T, Ikeda R, Nishikawa A. Analysis of Trichosporon isolates obtained from the houses of patients with summer-type hypersensitivity pneumonitis. J Clin Microbiol. 2004; 42: 5467-71.
3. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect Suppl 1. 2004; 48-66.
4. Girmenia C, Pagano L, Martino B, D'Antonio D, Fanci R, Specchia G, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005; 43: 1818-28.
5. Falk R, Wolf DG, Shapiro M, Polacheck I. Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole. J Clin Microbiol. 2003; 41: 911.
6. Wolf DG, Falk R, Hacham M, Theelen B, Boekhout T, Scorzetti G, et al. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol. 2001; 39: 4420-5.
7. Kanngurn S, Parichatikanond P, Pootong V, Vichyanond P. Chronic Granulomatous Disease with Disseminated Trichosporonosis: A Case Report. Siriraj J. 2001; 53: 542-8.
8. Anunnatsiri S, Chetchotisakd P, Mootsikapun P. Fungemia in non-HIV-infected patients: a five-year review. Int J Infect Dis. 2009; 13: 90-6.
9. Makimura K, Murayama SY, Yamaguchi H. Detection of a wide range of medically important fungi by the polymerase chain reaction. J Med Microbiol. 1994; 40: 358-64.
10. Sugita T, Nakajima M, Ikeda R, Matsushima T, Shinoda T. Sequence analysis of the ribosomal DNA intergenic spacer 1 regions of Trichosporon species. J Clin Microbiol. 2002; 40: 1826-30.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.
12. Kalkanci A, Sugita T, Arikan S, Yucesoy M, Ener B, Otag F, Kiraz N, Kustimur S, Sancak B, Evci C, Emektas G. Molecular identification, genotyping, and drug susceptibility of the basidiomycetous yeast pathogen Trichosporon isolated from Turkish patients. Medical Mycol. in press.
13. Ando M, Suga M, Nishiura Y, Miyajima M. Summer-type hypersensitivity pneumonitis. Intern Med. 1995; 34: 707-12.
14. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, Dzierzanowska D, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10. 5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2009; 47: 117-23.
15. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, Cano V, Tapia C, Perkins A, et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother. 2005; 49: 4026-34.